AIM ImmunoTech Inc. (AIM)
AMEX: AIM
· Real-Time Price · USD
2.64
-0.01 (-0.38%)
At close: Oct 16, 2025, 3:59 PM
2.58
-2.27%
After-hours: Oct 16, 2025, 07:40 PM EDT
-0.38% (1D)
| Bid | 2.59 |
| Market Cap | 7.16M |
| Revenue (ttm) | 121K |
| Net Income (ttm) | -16.17M |
| EPS (ttm) | -24.88 |
| PE Ratio (ttm) | -0.11 |
| Forward PE | -0.78 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.73 |
| Volume | 49,822 |
| Avg. Volume (20D) | 212,817 |
| Open | 2.68 |
| Previous Close | 2.65 |
| Day's Range | 2.60 - 2.73 |
| 52-Week Range | 2.33 - 36.00 |
| Beta | 0.43 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for AIM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-56.25%
AIM ImmunoTech shares are trading lower after the ...
Unlock content with
Pro Subscription
2 months ago
-14.29%
AIM stock has given up its prior gain. AIM ImmunoTech shares were trading higher after the company announced mid-year data from its Phase 2 DURIPANC trial.
1 week ago · proactiveinvestors.co.uk
Oxford BioDynamics shares soar 33% after unveiling breakthrough blood test for Chronic Fatigue SyndromeOxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) shares surged 33% on Wednesday after the company announced it had developed a highly accurate blood test to diagnose Chronic Fatigue Syndrome, a condition t...
1 week ago · proactiveinvestors.co.uk
Oxford BioDynamics unveils blood test for Chronic Fatigue Syndrome with 96% accuracyOxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) has developed what it calls a “first-in-class” blood test to diagnose Chronic Fatigue Syndrome, a breakthrough that could help end years of uncertainty for ...